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Serotonergic psychedelics, substances exerting their effects primarily through the serotonin 2A receptor
(5HT2AR), continue to comprise a substantial portion of reported new psychoactive substances (NPS). In
this paper five quantitative structure–activity relationship (QSAR) models for predicting the affinity of 5-
HT2AR ligands have been developed. The resulting models, exploiting the accessibility of the QSAR
equations, generate a useful tool for the investigation and identification of unclassified molecules. The
models have been built using a set of 375 molecules using Forge software, and the quality was
confirmed by statistical analysis, resulting in effective tools with respect to their predictive and
descriptive capabilities. The best performing algorithm among the machine learning approaches and the
classical field 3D-QSAR model were then combined to produce a consensus model and were exploited,
together with a pharmacophorefilter, to explore the 5-HT2AR activity of 523 105 natural products, to
classify a set of recently reported 5-HT2AR NPS and to design new potential active molecules. The
findings of this study should facilitate the identification and classification of emerging 5-HT2AR ligands
including NPS.Introduction
The 5-HT2A receptor (5HT2AR) is a surface G protein-coupled
receptor (GPCR) subtype of the 5-HT2 serotonin receptor
family. The receptor was rst discovered as a target of seroto-
nergic psychedelic drugs such as LSD and psilocybin, and later
it was proved to be a mediator of the action of many antipsy-
chotic drugs.1 Due to the wide expression of the receptor in the
central nervous system (CNS) and other tissues, several physi-
ological processes are mediated by the receptor: neuronal
excitation, hallucinations, out-of-body experiences, and fear; its
activation in the hypothalamus causes increases in several
hormonal levels; activation of the receptor produces potent
anti-inammatory effects in several tissues including cardio-
vascular; it also has a role in memory and learning, in
arthralgia, Alzheimer's disease, sleep paralysis, etc.2–6
Agonists and antagonists of this receptor are today used or
being studied for several clinical application, e.g. methysergide
(partial agonists) is used in treatment of migraine, AL-34662
(peripherally selective agonists) reduces the pressure inside
the eyes without crossing the blood–brain barrier and
producing hallucinogenic side effects;7 atypical antipsychotic
drugs such as risperidone, clozapine, quetiapine and asenapineand Forensic Sciences, King's College
ta@kcl.ac.uk; vincenzo.abbate@kcl.ac.uk
tion (ESI) available. See DOI:
the Royal Society of Chemistryare relatively potent antagonists of 5-HT2A, and nelotanserin
(inverse agonist) is studied for the treatment of insomnia.8
5HT2AR is also targeted for neuroimaging of patients with
major depressive disorder using PET imaging.9 However, due to
the natural expression of this receptor in the CNS, the receptor
is also targeted by new psychoactive substances (NPS) designed
for recreational use, and every year hundreds of NPS are
unearthed on the black market.
By early 2020, more than 950 NPS had been reported to the
United Nations Office on Drugs and Crime (UNODC); in
parallel, at the end of 2019 the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA) was monitoring around
790 NPS, 53 of which were reported for the rst time in Europe
in 2019.10,11 Over the time, the group of serotonergic psyche-
delics constituted a signicant proportion of these recently re-
ported NPS.12 The term serotonergic psychedelics includes
molecules that exert their pharmacological activity mainly by
means of interacting with the serotonin 5-HT2A receptor (5-
HT2AR).13 The class of serotonergic psychedelics is formed by
structurally diverse subclasses of compounds: the tryptamines
(e.g. psilocybin), the ergolines (e.g. lysergic acid diethylamide
(LSD)) and the phenylalkylamines (e.g. mescaline), Fig. 1.14
Mystical experiences, empathic feelings, alterations in
consciousness, sensory and somatic effects are the main effects
looked among users of 5HT2AR NPS ligands. However, severe
adverse effects, such as agitation, tachycardia, hyperthermia,
rhabdomyolysis, hypertension and seizures, can also frequently
























































































View Article Onlineemerging subclass of the phenylalkylamines psychedelics, cases
requiring hospitalization, suicide attempts, deaths and mass
poisoning (with e.g. BromoDragonFLY and 2C-E) have been
reported.17–19
QSAR models are utilized to assist predicting or under-
standing molecular/drug design within the chemical and
natural sciences.20,21 Few attempts have been performed to
build up QSAR models for the 5HT2AR, however all of them
have been produced through a constrained number of
compounds with comparable chemical structures and as
a result, only the affinities of a restricted class of compounds
could be determined.22–24
To facilitate the investigation of chemical datasets for 5HT2AR
ligands capabilities and to potentially identify emerging or future
NPS,25,26 here we report the development of ve quantitative
structure–activity relationship (QSAR) models for predicting the
affinity of 5-HT2AR ligands. Details of all the compounds having
experimentally determined Ki values were retrieved from the
literature and downloaded from CHEMBL. All models were built
using a set of 375 5-HT2AR ligands. Four out of ve such models
were built by machine learning algorithms (i.e. support vector
machine (SVM), k-nearest neighbors (kNN), random forest (RF)
and relevance vector machine (RVM)) and one model was built
with a eld-based methodology.27,28 Differently to previously
published 5HT2AR QSARmodels, the ones reported here include
a wide range of chemically different (sub)classes of compounds.
Moreover, the best performing tool from the generated machine
learning (SVM) and the eld based 3D-QSAR models were
employed to rank a dataset of recently reported 5HT2AR NPS
ligands and to screen a large dataset of natural products to
identify potential active molecules against 5-HT2AR.
All the reported QSAR models were developed using the
soware Forge. Conversely to classical 3D-QSAR modelling,
where molecular descriptors are calculated at the interception
points of a 3D grid, which surrounds the entire space of the
aligned molecules,29–31 the modelling calculation in Forge is
characterized by the use of probe positions that are dened
directly from the eld points of the aligned molecules in the
training set, and only these positions are then used to describe
the volume and the electrostatic potential of each molecule.32–35Methods
Biological data & 3D structures generation
The chemical structures of the 375 5-HT2AR ligands were
selected from the literature where the experimental Ki values areFig. 1 Structures of 5HT2AR psychoactive substances: the trypt-
amines (e.g. psilocybin), the ergolines (e.g. lysergic acid diethylamide
(LSD)) and the phenylalkylamines (e.g. mescaline).
14588 | RSC Adv., 2021, 11, 14587–14595reported and retrieved from ChEMBL Database (https://
www.ebi.ac.uk/chembl/g/). The biological data were all derived
from similar and comparable cellular based experiments. Ki
derived from displacement of [3H]-ketanserin, [125I]-DOI or
[3H]INBMeO from human 5HT2AR expressed CHO or HEK293
cells were used. The binding affinity data of the selected dataset
were converted into their negative decimal logarithm pKi (pKi ¼
log Ki). Collected pKi values fall into a range 5.19–10.40. The
structures of the studied molecules were built using Marvin
17.21.0, ChemAxon (https://www.chemaxon.com).36 The 2D
structures were subjected to molecular mechanics energy
minimization by Merck molecular force eld (MMFF94) using
the Marvin Sketch geometrical descriptors plugin.37 The
protonation states of the molecules were calculated assuming
a pH ¼ 7.0. The geometry of the obtained 3D structures was
further optimized at semi-empirical level using the parameter-
ized model number 3 (PM3) Hamiltonian as implemented in
MOPAC package (vMOPAC2016).38–40Compound alignment
All the 3D generated molecules, with their respective pKi values,
were imported into the computational chemistry soware Forge
(v10.4.2) for setting the machine learnings (SVM, kNN; RF and
RVM) and the eld-based 3D-QSAR model. Out of the 375
ligands for the 5HT2AR, we randomly selected (selection based
on activity stratication) 300 molecules (80%) as a training set
to build the models, while the remaining 75 compounds (20%)
served as test set to evaluate the models.41 For both training and
test sets, the selected molecules covered a wide range of bio-
logical activities: from 10.40 to 5.19 pKi for the training set and
from 10.00 to 5.34 pKi for the test set. All the molecules were
aligned to the three co-crystallized ligands of 5HT2AR in their
bioactive conformation inside the binding site retrieved from
the protein data bank (https://www.rcsb.org/) PDB ID: 6a93,
6a94 and 6wgt.42,43 8NU (risperidone) was the ligand selected for
6a93, ZOT (zotepine) was the ligand selected for 6a94, 7LD
((8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-
carboxamide) was the ligand selected for 6wgt.
The eld points (used as a descriptor of negative and positive
electrostatic, van der Waals shape, and hydrophobic areas)28 of
each molecule were generated using the extended electron
distribution (XED) force eld. The molecules in both training
set and test set were aligned to the reference compounds by
a most common substructure calculation (considering the
calculated eld points) employing a customized set-up.44 The
maximum number of conformations produced for each
compound was set to 500. The root-mean-square deviation of
nuclear positions (RMSD) cutoff for copy conformers was set to
0.5 Å. This parameter controls the likeness which two
conformers are accepted indistinguishable. The gradient cutoff
for conformer minimization was set to 0.1 kcal mol1. The
energy window was set to 2.5 kcal mol1. Conformations that
gave a minimized energy outside the energy window were dis-
carded. All the alignments were manually checked to ensure the
best possible alignment. All the eld points of the molecules
used for training the models were exploited to get a gauge© 2021 The Author(s). Published by the Royal Society of Chemistry






















0.88 0.75 0.73 0.13 0.29 0.31 0.45 4.21 6.24
SVM 0.99 0.74 0.73 0.01 0.30 0.06 0.44 0.84 6.21
kNN 0.66 0.66 0.49 0.38 0.56 0.48 0.56 6.75 7.70
RF 0.89 0.64 0.63 0.11 0.41 0.22 0.52 2.96 7.20
RVM 0.89 0.73 0.69 0.12 0.34 0.29 0.40 3.93 5.44
a Mean squared forecast error. b Mean absolute forecast error. c Mean absolute percentage forecast error.
Fig. 2 Five component field based QSAR model experimental vs.
























































































View Article Onlineinvariant set of sampling points, which reduced the number of
descriptors that must be considered. The sample values were
calculated using a distance of 1 Å between the sample points,
ensuring that all areas around the compounds that could
contribute to the activity were effectively described. All the
soware's parameters used for the conformation hunt, align-
ment, and build model calculations are reported in the ESI.†Results and discussion
Statistical analysis and results
For the calculation of the models, a partial least squares (PLS)
regression method specically employing the SIMPLS algo-
rithm was used for the eld model, whereas k-Nearest Neigh-
bors, Support Vector Machine, Relevance Vector Machine andFig. 3 Five component field based QSAR model experimental vs.
predicted pKi of the compounds in the test set.
© 2021 The Author(s). Published by the Royal Society of ChemistryRandom Forest were used in the supervised machine learning
models.45,46 Detailed information for the assembly and the
validation of all the models are reported in the ESI.† The 3D-
QSAR models' statistics are reported in Table 1. The 5-compo-
nent eld based model shows both good predictive and
descriptive capabilities, demonstrated by the good r2 (0.88) and
q2 (0.75) values for the training and the cross-validated training
set (Fig. 2).47 The plots of experimental vs. predicted affinities
for the compounds in the test set (Fig. 3) show accurate
predictions with only a few outliers and an excellent cross-
validated r2 (0.73). Regarding the supervised learning models
(SVM, kNN, RF and RVM), the r2 of the models ranked between
0.99 and 0.66, the q2 between 0.74 and 0.66 and the r2 test
between 0.73 and 0.79 (Table 1). According to these results, the
best performing algorithm among the supervised machine
learning models is the SVM. The model experimental vs. pre-
dicted pKi of the compounds in the training set and in the test
set for the SVM model are reported in Fig. 4 and 5.
The 3D visualizations of the eld QSAR model is shown in
Fig. 6, where the 3D-QSAR coefficients for the two models are
superimposed to the most potent molecule in the training set
and to risperidone, that was used in the alignment process
(PDBID: 6a93). The 3D-QSAR model is portrayed by both steric
and electrostatic impacts. The model outlines zones where the
equation proposes that the nearby areas have a strong effect on
ligand-receptor affinity (Fig. 6). The bigger the points (portrayed
as octahedrons), the stronger is the relationship between the
electrostatic and steric areas in that position. The higher affinity
related to the electrostatic potential is delineated in red for the
positive values and in blue for the negative ones. For the stericFig. 4 SVM QSAR model experimental vs. predicted pKi of the
compounds in the training set.
RSC Adv., 2021, 11, 14587–14595 | 14589
Fig. 7 The model map is superimposed to risperidone. Molecular
insight of SAR mechanism models, revealing the different lead opti-
mization sites of active compounds. Red color shows positive field
region controlling the activity, and blue color the negative ones. Green
color shows favorable shape/hydrophobic regions, and purple color
the unfavorable ones.
Fig. 5 SVM QSAR model experimental vs. predicted pKi of the
























































































View Article Onlinebulk, the green region leads to higher receptor affinity while the
violet zone leads to lower affinity.
To uncover the key highlights of the examined set of
compounds against the focused 5HT2AR, a structure–activity
relationship (SAR) study was performed through activity-atlas
(AA) visualization program. AA is a qualitative strategy valu-
able for summarizing structure–activity data into 3D maps,
which helps within the design and optimization of new
compounds. This strategy analyses the SAR of a set of aligned
compounds as a function of their electrostatic, hydrophobic,
and shape properties through a Bayesian approach to require
a global see of the information in a qualitative way. Fig. 7 and 8
show the results of the AA calculations for the 5HT2AR. The
model map is superimposed to risperidone in its bioactive
conformation retrieved from the crystal structure (6a93). Elec-
trostatic, hydrophobic, and shape features are highlighted by
the different colors on the map. In the red area, a more positive
electrostatic eld increases the receptor-affinity, whereas in the
blue region a more negative electrostatic eld increases theFig. 6 Electrostatic and steric coefficients for the field model. (A) Electros
PD BID: 6a93) (up) and the most potent compounds in the training set (d
most potent compounds in the training set (down). (C) Contributions to p
the training set (down).
14590 | RSC Adv., 2021, 11, 14587–14595interaction energies. The violet and the green areas account for
the steric and bulk/hydrophobic interactions. In the violet area,
a steric/bulk interaction decreases the affinity, whereas in the
green area a steric/bulk interaction improves the binding
affinity.
Risperidone can be dissected in three different regions: (i)
the uorobenzisoxazol ring; (ii) the pyperidine nucleus; (iii) the
tetrahydropyridopyrimidinone ring. Two main hydrophobic
areas are described by the AA model for the uorobenzisoxazol
ring and the tetrahydropyridopyrimidinone ring, whereas the
pyperidine nucleus is mainly located close to a red area, where
a more positive electrostatic eld increases the receptor-affinity.
The occupancy of both hydrophobic area is fundamental for the
affinity; indeed, ligands that do not bear any substituent in this
area result in low affinity (e.g. (S)-1-(2,5-dimethoxyphenyl)
propan-2-amine, pKi ¼ 5.28, training set; 5-hydroxy-8-(4-
methyl-1,4-diazepan-1-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one, pKitatic coefficients superimposed to risperidone (used for the alignment,
own). (B) Steric coefficients superimposed to risperidone (up) and the
redicted affinity for risperidone (up) and themost potent compounds in
























































































View Article Online¼ 5.19, training set). Inside the binding pocket, risperidone
adopts an extended conformation, as showed by the AA model.
The basic nitrogen of the pyperidine nucleus forms a salt bridge
with Asp155, this interaction being well highlighted in the AA
model by the red area surrounding the nitrogen of the pyper-
idine. This salt bridge is strictly conserved in the structures of
aminergic receptors and is thought to be stabilized by the
conserved hydrogen bond between Asp155 and Tyr370. The
uorobenzisoxazol ring of risperidone is placed in the bottom
hydrophobic cle represented by a green, favourable hydro-
phobic interaction, by the AA model. This ring interacts with
Ser159 by a CH–p interaction and with Ile163, Phe243 and
Phe332 by hydrophobic interactions. As already stated, the
occupancy of this area is fundamental for ligand affinity;
indeed, mutation of these residues will result in a loss in affinity
for 5HT2AR ligands.42 The tetrahydropyridopyrimidinone ring
is located in the other hydrophobic area of the AA model,
interacting with Leu228 and Val366 of the protein.NPS identication
Together with synthetic cannabinoids, cathinone derivatives,
designer GABA-A/B receptor agonists and novel synthetic
opioids, recently emerged and unregulated molecules with high
5HT2AR affinity can be considered NPS. These substances –
once identied – are normally screened through cellular in vitro
tests, that are expensive and time consuming. To exploit theFig. 8 The model AA map is superimposed to risperidone inside 5HT2A
© 2021 The Author(s). Published by the Royal Society of Chemistrypredictive capabilities of our models we selected 29 recently
reported NPS (phenethylamines, phenylisopropylamines and N-
benzylphenethylamines)48 with measured EC50, by means of b-
arrestin 2 recruitment in 5HT2AR and compared the in vitro
results with the modelled results of the eld based and best
machine learning (SVM) based models. Despite the Ki measures
the effective interaction of the molecule with the receptor
whereas the EC50 measures the effective concentration at 50%
of the total biological effect, the two Ki and EC50 are held
together by the Cheng–Prusoff equation.49 This means that for
a giving set of agonist or antagonist agents for the 5HT2AR, the
most potent agonist or antagonist will have the lowest Ki
(highest pKi). Of note, the models here reported are not able to
distinguish between agonist or antagonist action but are able to
rank sets of agonists or antagonists according to their receptor
affinity.
The results of the experimental EC50 vs. the calculated pKi
are reported in Fig. 9 and Table S3.† Interestingly, both the eld
based and the SVMmodels well performed in the ranking of the
29 compounds, with a slightly better performance for the
machine learning model. Both models are able to rank the
compounds with a good linearity between the calculated and
the experimental values, with r2 of 0.7105 and 0.7799 for the
eld and the SVM based models, respectively. More impor-
tantly, the models were able to distinctly classify potent
compounds from not-potent ones i.e. the ve most potent
compounds (25C-NBOH, 25E-NBOMe, 25D-NBOMe, 25I-R (6a93). 2D interaction between risperidone and 5HT2AR.
RSC Adv., 2021, 11, 14587–14595 | 14591
























































































View Article OnlineNBOMe, 25I-NBOH) in the set were identied among the most
potent compounds for 5HT2AR activity by both models. Anal-
ogously, the ve less potent molecules (25H-NBF, b-k-2C-B, 2C-
H, DOH, N-Me-2C-H) were also identied as weak binders by









8.75Finding NPS from natural databases and scaffold hopping
analysis
In order to exploit the predicting capability of the models to
retrieve novel 5HT2AR binders, the QSAR equations were used
to screen for potential active molecules in three databases of
natural compounds for a total of 523,105 molecules. Super
Natural Product (SNP), ZINC and MolPort Natural (MPN) were
selected as a database of natural compounds.50 The 523 105
molecules were rstly ltered through a pharmacophore lter
using pharmit (http://pharmit.csb.pitt.edu). The chemical
database was screened against the pharmacophore models
(generated from the three co-cristallyzed ligands of 5HT2AR in
their bioactive conformation retrieved from the protein data
bank PDB ID: 6a93, 6a94 and 6wgt) to nd the best matches in
terms of root mean square distance (RMSD) between pharma-
cophore query features and corresponding ligand points. 910
compounds with the lowest RMSD value (less than 0.75) were
selected for further evaluation in our models. The eld based
and the SVM QSAR models were then used to score the ltered
dataset of 910 compounds. With this objective in mind, all of
the molecules were aligned to the models as described in the
compound alignment paragraph. The six most potent mole-
cules identied by means of the calculated pKi from both
models are reported in Table 2 and the whole set in Table S4.†
Despite molecules 1, 3 and 6 have not been reported as 5HT
receptor binders (molecule 1 class was reported for the treat-
ment of cancer51 and molecule 652 is derived from pyridyloxy
carboxylic acid commonly used as herbicidal whereas no bio-
logical activity is reported for molecule 3), molecule 2, 4 and 5
have been tested for their activity against serotoninergic
receptors showing the potentiality of the models to nd new
hits among library of compounds and would deserve further
research investigation to better understand the potential
5HT2AR activity of high ranked compounds.53,54
All themolecules selected asmost potent (Table 2) are able to
interact with the 5HT2AR correctly inside its binding site. The14592 | RSC Adv., 2021, 11, 14587–14595protonated nitrogen in molecules 2–6 is forming the funda-
mental salt-bridge with ASP155, moreover the aromatic part of
the molecules are accommodated in the two hydrophobic
pockets inside the receptor formed by SER131, TYR139,
ASN363, LEU362, LEU228, VAL366 or PHE340, PHE243,
TRP336, ILE163, SER242, THR160, SER159 gaining stability
thought hydrophobic interactions.
The predictive capabilities of the model were then used for
a scaffold-hopping study of the most potent compounds in the
training set for the generation of a library of new compounds© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 10 Scaffold hopping series 1–3 derived from the most potent
























































































View Article Onlinewith high affinity for the receptor. The molecule was divided in
three parts and a scaffold hopping analysis was performed as
already reported by us (ref. 21, 25 and 26) for each part (Fig. 10).
In series 1 the benzo[d]isothiazole was substituted, in series 2
the ethyl-2,3-dihydro-1H-indene core was substituted and in
series 3 the terminal phenylacetamide was substituted. The
piperazine nucleus was not replaced due to the importantTable 3 Top 6 ligands from the scaffold replacement series 1–3.
Molecules 7 and 8, series 1. Molecules 9 and 10, series 2. Molecules 11










© 2021 The Author(s). Published by the Royal Society of Chemistryinteraction with ASP155. The resulting molecules were then
evaluated by the superposition on the 3D-QSARmodels. Overall,
the results showed in Table 3 (best two molecules for each
series) indicate that the scaffold replacement generated new
structures with the appropriate chemical features for the
binding to the 5HT2AR and the selected compounds resulted
more potent than their precursor, showing again the potential
of the models to identify new hits among library of compounds
and would deserve further research investigation to better
understand the potential 5HT2AR activity.Conclusions
The present study deals with the development of different eld
based and machine learning based 3D-QSAR models for the
prediction of the affinity for 5HT2AR ligands and their succes-
sive use as a tool for ranking 5HT2AR NPS, the screening of
a large dataset of natural molecules and new designed
compounds. Forge was used to build a statistically robust 3D-
QSAR model using a set of 375 molecules for the 5HT2AR
covering a whole range of different chemical classes of the
ligands for 5HT2A protein. To the best of our knowledge, this is
the rst attempt of 3D-QSAR modelling for this subtype of
serotoninergic receptor which includes such a wide number
and range of molecular structures and accounts for the
observed SAR. The 3D-QSAR models showed high statistical
quality and robust predictive potential capability, particularly
the eld based and the SVM which were shown to possess the
best statistical quality. Visualization of the model by means of
AA allowed processing data in a 3D map format accounting for
both steric and electrostatic effects and allow for a ration-
alization of both potency and selectivity. The eld-based model
and the SVM-based model were then used to rank a dataset of
recently reported 5HT2AR NPS and screen a dataset of natural
products for potential active molecules against 5HT2AR. Inter-
estingly, the models were able to rank the experimental EC50
and the calculated Ki of the NPS in a linear manner and to
identify alkaloids already tested for their activity against the
5HT2AR. The 3D-QSAR models here reported will guarantee,
prospectively, fruitful applications to speed up the design of
novel therapeutic molecules for 5HT2AR as well as the
identication/classication of NPS acting on 5HT2AR.25,26Conflicts of interest
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